TARS
Tarsus Pharmaceuticals, Inc.
Price Chart
Latest Quote
$63.16
+0.61 (+0.98%)
Current Price
| Previous Close | $62.55 |
| Open | $63.38 |
| Day High | $64.24 |
| Day Low | $62.37 |
| Volume | 375,594 |
Stock Information
| Shares Outstanding | 43.02M |
| Total Debt | $88.68M |
| Cash Equivalents | $388.73M |
| Revenue | $535.08M |
| Net Income | $-48.27M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $2.72B |
| EPS (TTM) | $-1.11 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $2.32B |
| Sales | $535.08M |
| Income | $-48.27M |
| Book/sh | $8.07 |
| Cash/sh | $9.04 |
| Employees | 370 |
Financial Ratios
| Quick Ratio | 3.53 |
| Current Ratio | 3.74 |
| Debt/Eq | 25.41 |
Returns & Margins
| ROA | -5.87% |
| ROE | -13.96% |
| Gross Margin | 79.98% |
| Operating Margin | -3.78% |
| Profit Margin | -9.02% |
Ownership
| Insider Ownership | 3.07% |
| Institutional Ownership | 109.83% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 22.03 |
| P/S | 5.08 |
| P/B | 7.83 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $94.11 |
Technical Indicators
| SMA20 | $60.80 |
| SMA50 | $63.23 |
| SMA200 | $68.26 |
| RSI | 63.39 |
| ATR | 2.7343 |
| Shares Float | 32.12M |
| Short Float | 12.31% |
| Short Ratio | 6.59 |
| Volatility | 0.51 |
| Rel Volume | 0.65 |
Performance History
| Week | +0.88% |
| Month | +3.05% |
| Quarter | -5.38% |
| 6 Months | -19.32% |
| YTD | -21.80% |
| Year | +60.22% |
| 3 Years | +233.30% |
| 5 Years | +79.08% |
| 10 Years | +206.90% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $63.16 | 375,594 |
| 2026-06-17 | $62.55 | 462,300 |
| 2026-06-16 | $60.80 | 718,800 |
| 2026-06-15 | $61.85 | 502,400 |
| 2026-06-12 | $61.95 | 267,300 |
| 2026-06-11 | $62.61 | 399,700 |
| 2026-06-10 | $61.27 | 319,900 |
| 2026-06-09 | $61.55 | 615,600 |
| 2026-06-08 | $59.64 | 443,400 |
| 2026-06-05 | $59.28 | 370,100 |
| 2026-06-04 | $60.34 | 433,000 |
| 2026-06-03 | $58.76 | 833,900 |
| 2026-06-02 | $57.41 | 1,588,300 |
| 2026-06-01 | $58.93 | 440,000 |
| 2026-05-29 | $59.40 | 615,900 |
| 2026-05-28 | $59.54 | 1,054,600 |
| 2026-05-27 | $60.06 | 562,800 |
| 2026-05-26 | $61.16 | 1,068,600 |
| 2026-05-22 | $62.26 | 259,600 |
| 2026-05-21 | $63.48 | 293,700 |
| 2026-05-20 | $64.79 | 1,229,200 |
| 2026-05-19 | $61.29 | 640,500 |
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction. In addition, it is developing the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. The company has a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for the development and commercialization of TP-03 in China for the treatment of Demodex blepharitis and meibomian gland disease. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
đ° Latest News
A Look At Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Strength And Perceived Discount
Simply Wall St. âĸ 2026-06-10T15:12:55Z
This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million
Motley Fool âĸ 2026-05-24T14:39:48Z
This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter
Motley Fool âĸ 2026-05-24T14:33:59Z
Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Weakness And Long Term Gains
Simply Wall St. âĸ 2026-05-12T04:34:41Z
Is It Time To Reassess Tarsus Pharmaceuticals (TARS) After Its Recent Share Price Swings?
Simply Wall St. âĸ 2026-05-11T16:22:05Z
Tarsus Pharmaceuticals Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-07T06:07:15Z
Tarsus Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-07T00:37:24Z
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Beats Revenue Estimates
Zacks âĸ 2026-05-06T22:30:10Z
Amgen (AMGN) Q1 Earnings and Revenues Beat Estimates
Zacks âĸ 2026-04-30T21:15:01Z
Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Moves And Ongoing Losses
Simply Wall St. âĸ 2026-04-03T16:17:52Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $30,684,000 | $12,826,000 | $1,593,000 | $955,000 |
| Cost Of Revenue | $30,684,000 | $12,826,000 | $1,593,000 | $955,000 |
| Total Revenue | $451,360,000 | $182,953,000 | $17,447,000 | $25,816,000 |
| Operating Revenue | $451,360,000 | $182,953,000 | $17,447,000 | $25,816,000 |
| Expenses | ||||
| Interest Expense | $8,342,000 | $7,447,000 | $3,225,000 | $2,064,000 |
| Total Expenses | $522,329,000 | $303,522,000 | $160,605,000 | $88,528,000 |
| Other Income Expense | $-202,000 | $-2,150,000 | $274,000 | $-683,000 |
| Other Non Operating Income Expenses | $-202,000 | $-206,000 | $274,000 | $86,000 |
| Net Non Operating Interest Income Expense | $6,812,000 | $7,165,000 | $6,991,000 | $1,300,000 |
| Total Other Finance Cost | $593,000 | $402,000 | $121,000 | $135,000 |
| Interest Expense Non Operating | $8,342,000 | $7,447,000 | $3,225,000 | $2,064,000 |
| Operating Expense | $491,645,000 | $290,696,000 | $159,012,000 | $87,573,000 |
| General And Administrative Expense | - | - | - | $44,949,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-66,418,000 | $-115,554,000 | $-135,893,000 | $-62,091,000 |
| Net Interest Income | $6,812,000 | $7,165,000 | $6,991,000 | $1,300,000 |
| Interest Income | $15,747,000 | $15,014,000 | $10,337,000 | $3,499,000 |
| Normalized Income | $-66,418,000 | $-113,610,000 | $-135,893,000 | $-61,322,050 |
| Net Income From Continuing And Discontinued Operation | $-66,418,000 | $-115,554,000 | $-135,893,000 | $-62,091,000 |
| Total Operating Income As Reported | $-70,969,000 | $-120,569,000 | $-143,158,000 | $-62,712,000 |
| Net Income Common Stockholders | $-66,418,000 | $-115,554,000 | $-135,893,000 | $-62,091,000 |
| Net Income | $-66,418,000 | $-115,554,000 | $-135,893,000 | $-62,091,000 |
| Net Income Including Noncontrolling Interests | $-66,418,000 | $-115,554,000 | $-135,893,000 | $-62,091,000 |
| Net Income Continuous Operations | $-66,418,000 | $-115,554,000 | $-135,893,000 | $-62,091,000 |
| Pretax Income | $-64,359,000 | $-115,554,000 | $-135,893,000 | $-62,095,000 |
| Special Income Charges | $0 | $-1,944,000 | $0 | $0 |
| Interest Income Non Operating | $15,747,000 | $15,014,000 | $10,337,000 | $3,499,000 |
| Operating Income | $-70,969,000 | $-120,569,000 | $-143,158,000 | $-62,712,000 |
| Gross Profit | $420,676,000 | $170,127,000 | $15,854,000 | $24,861,000 |
| Per Share | ||||
| Diluted EPS | $-1.59 | $-3.07 | $-4.62 | $-2.52 |
| Basic EPS | $-1.59 | $-3.07 | $-4.62 | $-2.52 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $-50 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-54,201,000 | $-104,938,000 | $-131,791,000 | $-58,936,000 |
| Total Unusual Items | $0 | $-1,944,000 | $0 | $-769,000 |
| Total Unusual Items Excluding Goodwill | $0 | $-1,944,000 | $0 | $-769,000 |
| Reconciled Depreciation | $1,816,000 | $1,225,000 | $877,000 | $326,000 |
| EBITDA (Bullshit earnings) | $-54,201,000 | $-106,882,000 | $-131,791,000 | $-59,705,000 |
| EBIT | $-56,017,000 | $-108,107,000 | $-132,668,000 | $-60,031,000 |
| Diluted Average Shares | $41,784,014 | $37,604,538 | $29,383,276 | $24,619,700 |
| Basic Average Shares | $41,784,014 | $37,604,538 | $29,383,276 | $24,619,700 |
| Diluted NI Availto Com Stockholders | $-66,418,000 | $-115,554,000 | $-135,893,000 | $-62,091,000 |
| Tax Provision | $2,059,000 | $0 | $0 | $-4,000 |
| Research And Development | $64,322,000 | $53,386,000 | $50,312,000 | $42,624,000 |
| Selling General And Administration | $427,323,000 | $237,310,000 | $108,700,000 | $44,949,000 |
| Other Special Charges | - | $1,944,000 | - | - |
| Gain On Sale Of Security | - | $-792,000 | $376,000 | $-769,000 |
| Other Gand A | - | - | - | $44,949,000 |
Fetched: 2026-06-16
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $336,060,000 | $216,208,000 | $193,121,000 | $192,900,000 |
| Total Assets | $562,158,000 | $376,991,000 | $265,491,000 | $227,863,000 |
| Total Non Current Assets | $39,376,000 | $20,286,000 | $9,360,000 | $2,488,000 |
| Other Non Current Assets | $6,395,000 | $6,094,000 | $1,514,000 | $585,000 |
| Goodwill And Other Intangible Assets | $7,366,000 | $8,326,000 | $3,867,000 | $0 |
| Current Assets | $522,782,000 | $356,705,000 | $256,131,000 | $225,375,000 |
| Restricted Cash | $560,000 | $0 | - | - |
| Prepaid Assets | $13,473,000 | $14,650,000 | $7,868,000 | $4,767,000 |
| Inventory | $4,372,000 | $2,620,000 | $3,107,000 | $0 |
| Receivables | $87,109,000 | $48,059,000 | $17,714,000 | $3,582,000 |
| Other Receivables | $2,052,000 | $1,299,000 | $1,093,000 | $3,582,000 |
| Accounts Receivable | $85,057,000 | $46,760,000 | $16,621,000 | $0 |
| Cash Cash Equivalents And Short Term Investments | $417,268,000 | $291,376,000 | $227,442,000 | $217,026,000 |
| Cash And Cash Equivalents | $183,641,000 | $94,819,000 | $224,947,000 | $71,660,000 |
| Cash Equivalents | - | - | $224,947,000 | $71,660,000 |
| Non Current Prepaid Assets | - | - | - | $82,000 |
| Financial Assets | - | - | - | $108,000 |
| Taxes Receivable | - | - | - | $126,000 |
| Accrued Interest Receivable | - | - | - | $178,000 |
| Debt | ||||
| Total Debt | $72,438,000 | $72,453,000 | $30,217,000 | $20,155,000 |
| Long Term Debt And Capital Lease Obligation | $72,438,000 | $71,845,000 | $29,819,000 | $19,434,000 |
| Long Term Debt | $72,438,000 | $71,845,000 | $29,819,000 | $19,434,000 |
| Current Debt And Capital Lease Obligation | - | $608,000 | $398,000 | $721,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $218,732,000 | $152,457,000 | $68,503,000 | $34,963,000 |
| Total Non Current Liabilities Net Minority Interest | $83,037,000 | $71,845,000 | $31,567,000 | $19,534,000 |
| Other Non Current Liabilities | $10,599,000 | - | $1,748,000 | $100,000 |
| Current Liabilities | $135,695,000 | $80,612,000 | $36,936,000 | $15,429,000 |
| Other Current Liabilities | $22,179,000 | $18,320,000 | - | - |
| Payables And Accrued Expenses | $113,516,000 | $61,684,000 | $36,538,000 | $14,708,000 |
| Payables | $27,298,000 | $12,739,000 | $18,426,000 | $5,498,000 |
| Other Payable | $9,100,000 | $3,320,000 | $654,000 | - |
| Total Tax Payable | $1,811,000 | $0 | - | $14,000 |
| Income Tax Payable | $1,811,000 | $0 | - | $14,000 |
| Accounts Payable | $16,387,000 | $9,419,000 | $17,772,000 | $5,498,000 |
| Derivative Product Liabilities | - | - | - | $48,000 |
| Interest Payable | - | - | - | $215,000 |
| Equity | ||||
| Common Stock Equity | $343,426,000 | $224,534,000 | $196,988,000 | $192,900,000 |
| Total Equity Gross Minority Interest | $343,426,000 | $224,534,000 | $196,988,000 | $192,900,000 |
| Stockholders Equity | $343,426,000 | $224,534,000 | $196,988,000 | $192,900,000 |
| Gains Losses Not Affecting Retained Earnings | $381,000 | $179,000 | $-2,000 | $-74,000 |
| Other Equity Adjustments | $381,000 | $179,000 | $-2,000 | $-74,000 |
| Retained Earnings | $-426,628,000 | $-360,210,000 | $-244,656,000 | $-108,763,000 |
| Other | ||||
| Ordinary Shares Number | $42,553,931 | $38,349,826 | $34,211,190 | $26,727,458 |
| Share Issued | $42,553,931 | $38,349,826 | $34,211,190 | $26,727,458 |
| Tangible Book Value | $336,060,000 | $216,208,000 | $193,121,000 | $192,900,000 |
| Invested Capital | $415,864,000 | $296,379,000 | $226,807,000 | $212,334,000 |
| Working Capital | $387,087,000 | $276,093,000 | $219,195,000 | $209,946,000 |
| Capital Lease Obligations | $0 | $608,000 | $398,000 | $721,000 |
| Total Capitalization | $415,864,000 | $296,379,000 | $226,807,000 | $212,334,000 |
| Additional Paid In Capital | $769,667,000 | $584,559,000 | $441,641,000 | $301,732,000 |
| Capital Stock | $6,000 | $6,000 | $5,000 | $5,000 |
| Common Stock | $6,000 | $6,000 | $5,000 | $5,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Current Capital Lease Obligation | $0 | $608,000 | $398,000 | $721,000 |
| Current Accrued Expenses | $86,218,000 | $48,945,000 | $18,112,000 | $9,210,000 |
| Investments And Advances | $3,870,000 | $3,000,000 | $631,000 | $371,000 |
| Net PPE | $21,745,000 | $2,866,000 | $3,348,000 | $1,532,000 |
| Accumulated Depreciation | $-2,098,000 | $-1,976,000 | $-1,290,000 | $-546,000 |
| Gross PPE | $23,843,000 | $4,842,000 | $4,638,000 | $2,078,000 |
| Leases | $9,925,000 | $794,000 | $680,000 | $425,000 |
| Other Properties | $11,653,000 | $1,323,000 | $2,047,000 | $742,000 |
| Machinery Furniture Equipment | $2,265,000 | $2,725,000 | $1,911,000 | $911,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $2,962,000 | $2,006,000 | $182,000 | - |
| Work In Process | $1,410,000 | $614,000 | $392,000 | - |
| Other Short Term Investments | $233,627,000 | $196,557,000 | $2,495,000 | $145,366,000 |
| Raw Materials | - | $0 | $2,533,000 | - |
| Long Term Capital Lease Obligation | - | - | - | $52,000 |
| Pensionand Other Post Retirement Benefit Plans Current | - | - | - | $0 |
| Treasury Shares Number | - | - | - | - |
Fetched: 2026-06-16
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-22,310,000 | $-89,594,000 | $-122,995,000 | $-49,536,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-12,451,000 | $-83,027,000 | $-117,493,000 | $-49,030,000 |
| Cash Flow From Continuing Operating Activities | $-12,451,000 | $-83,027,000 | $-117,493,000 | $-49,030,000 |
| Operating Gains Losses | - | $2,145,000 | $-117,000 | $501,000 |
| Investing Activities | ||||
| Capital Expenditure | $-9,859,000 | $-6,567,000 | $-5,502,000 | $-506,000 |
| Investing Cash Flow | $-42,115,000 | $-199,195,000 | $140,604,000 | $-144,629,000 |
| Cash Flow From Continuing Investing Activities | $-42,115,000 | $-199,195,000 | $140,604,000 | $-144,629,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $134,771,000 | $98,287,000 | $118,599,000 | $74,352,000 |
| Financing Cash Flow | $143,388,000 | $154,656,000 | $130,176,000 | $93,987,000 |
| Cash Flow From Continuing Financing Activities | $143,388,000 | $154,656,000 | $130,176,000 | $93,987,000 |
| Net Common Stock Issuance | $134,771,000 | $98,287,000 | $118,599,000 | $74,352,000 |
| Common Stock Issuance | $134,771,000 | $98,287,000 | $118,599,000 | $74,352,000 |
| Net Other Financing Charges | - | $-35,400,000 | - | $-950,000 |
| Net Preferred Stock Issuance | - | - | - | - |
| Preferred Stock Issuance | - | - | - | - |
| Other | ||||
| Issuance Of Debt | $0 | $75,000,000 | $10,000,000 | $20,000,000 |
| Interest Paid Supplemental Data | $8,342,000 | $7,662,000 | $2,880,000 | $1,675,000 |
| End Cash Position | $186,203,000 | $97,381,000 | $224,947,000 | $71,660,000 |
| Beginning Cash Position | $97,381,000 | $224,947,000 | $71,660,000 | $171,332,000 |
| Changes In Cash | $88,822,000 | $-127,566,000 | $153,287,000 | $-99,672,000 |
| Proceeds From Stock Option Exercised | $8,617,000 | $16,769,000 | $1,577,000 | $585,000 |
| Net Issuance Payments Of Debt | $0 | $75,000,000 | $10,000,000 | $20,000,000 |
| Net Long Term Debt Issuance | $0 | $75,000,000 | $10,000,000 | $20,000,000 |
| Long Term Debt Issuance | $0 | $75,000,000 | $10,000,000 | $20,000,000 |
| Net Investment Purchase And Sale | $-32,256,000 | $-192,628,000 | $146,106,000 | $-144,123,000 |
| Sale Of Investment | $361,800,000 | $73,000,000 | $174,770,000 | $5,315,000 |
| Purchase Of Investment | $-394,056,000 | $-265,628,000 | $-28,664,000 | $-149,438,000 |
| Net Intangibles Purchase And Sale | $0 | $-5,000,000 | $-4,000,000 | $0 |
| Purchase Of Intangibles | $0 | $-5,000,000 | $-4,000,000 | $0 |
| Net PPE Purchase And Sale | $-9,859,000 | $-1,567,000 | $-1,502,000 | $-506,000 |
| Purchase Of PPE | $-9,859,000 | $-1,567,000 | $-1,502,000 | $-506,000 |
| Change In Working Capital | $14,638,000 | $3,844,000 | $306,000 | $-951,000 |
| Change In Other Current Liabilities | $45,389,000 | $37,560,000 | $8,888,000 | $-67,000 |
| Change In Other Current Assets | $-527,000 | $572,000 | $-718,000 | $-215,000 |
| Change In Payables And Accrued Expense | $8,862,000 | $5,122,000 | $12,263,000 | $3,542,000 |
| Change In Accrued Expense | $1,956,000 | $2,578,000 | $7,726,000 | $2,721,000 |
| Change In Payable | $6,906,000 | $2,544,000 | $4,537,000 | $821,000 |
| Change In Account Payable | $6,906,000 | $2,544,000 | $4,537,000 | $821,000 |
| Change In Prepaid Assets | $1,716,000 | $-7,019,000 | $-2,889,000 | $-721,000 |
| Change In Inventory | $-1,751,000 | $-2,046,000 | $-3,107,000 | $0 |
| Change In Receivables | $-39,051,000 | $-30,345,000 | $-14,131,000 | $-3,490,000 |
| Changes In Account Receivables | $-38,297,000 | $-30,139,000 | $-16,621,000 | $0 |
| Other Non Cash Items | $1,275,000 | $1,117,000 | $926,000 | $773,000 |
| Stock Based Compensation | $41,720,000 | $27,818,000 | $19,830,000 | $13,460,000 |
| Unrealized Gain Loss On Investment Securities | $0 | $591,000 | $-259,000 | $268,000 |
| Amortization Of Securities | $-5,482,000 | $-4,213,000 | $-3,163,000 | $-1,316,000 |
| Depreciation Amortization Depletion | $1,816,000 | $1,225,000 | $877,000 | $326,000 |
| Depreciation And Amortization | $1,816,000 | $1,225,000 | $877,000 | $326,000 |
| Amortization Cash Flow | $961,000 | $540,000 | $133,000 | $0 |
| Amortization Of Intangibles | $961,000 | $540,000 | $133,000 | $0 |
| Depreciation | $855,000 | $685,000 | $744,000 | $326,000 |
| Net Income From Continuing Operations | $-66,418,000 | $-115,554,000 | $-135,893,000 | $-62,091,000 |
| Gain Loss On Investment Securities | - | $201,000 | $-117,000 | $501,000 |
| Net Foreign Currency Exchange Gain Loss | - | - | $0 | $1,000 |
| Gain Loss On Sale Of PPE | - | - | - | $0 |
Fetched: 2026-06-16